APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Peptide-Based Vaccines for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide-Based Vaccines for Cancer Market Outlook and Growth Opportunities 2026

Report ID 174023590430 December 2025191 pages

Choose your research edition.

Industry ResearchPeptide-Based Vaccines for Cancer Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-Based Vaccines for Cancer Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Peptide-Based Vaccines for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-Based Vaccines for Cancer Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-Based Vaccines for Cancer Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Peptide-Based Vaccines for Cancer market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide-Based Vaccines for Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide-Based Vaccines for Cancer market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide-Based Vaccines for Cancer market include ACT, Almac, AmbioPharm, Anergis, Immatics, Immatics, Marker Therapeutics, Inc., OncoPep and Sellas Life Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide-Based Vaccines for Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide-Based Vaccines for Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide-Based Vaccines for Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide-Based Vaccines for Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide-Based Vaccines for Cancer Segment by Company

ACT

Almac

AmbioPharm

Anergis

Immatics

Immatics

Marker Therapeutics, Inc.

OncoPep

Sellas Life Sciences

Ultimovacs

Peptide-Based Vaccines for Cancer Segment by Type

Synthetic Polypeptide Vaccines

Recombinant Polypeptide Vaccine

Other

Peptide-Based Vaccines for Cancer Segment by Application

Infectious Disease Prevention

Cancer Immunotherapy

Other

Peptide-Based Vaccines for Cancer Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Peptide-Based Vaccines for Cancer status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peptide-Based Vaccines for Cancer market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide-Based Vaccines for Cancer significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide-Based Vaccines for Cancer competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Based Vaccines for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-Based Vaccines for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Based Vaccines for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide-Based Vaccines for Cancer market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide-Based Vaccines for Cancer industry.

Chapter 3: Detailed analysis of Peptide-Based Vaccines for Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peptide-Based Vaccines for Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peptide-Based Vaccines for Cancer in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide-Based Vaccines for Cancer Industry Trends Table 2. Peptide-Based Vaccines for Cancer Industry Drivers Table 3. Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges Table 4. Peptide-Based Vaccines for Cancer Industry Restraints Table 5. Global Peptide-Based Vaccines for Cancer Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide-Based Vaccines for Cancer Revenue Share by Company (2021-2026) Table 7. Global Peptide-Based Vaccines for Cancer Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Peptide-Based Vaccines for Cancer Sales Volume Share by Company (2021-2026) Table 9. Global Peptide-Based Vaccines for Cancer Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Peptide-Based Vaccines for Cancer Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peptide-Based Vaccines for Cancer Key Company Manufacturing Base & Headquarters Table 12. Global Peptide-Based Vaccines for Cancer Company, Product Type & Application Table 13. Global Peptide-Based Vaccines for Cancer Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide-Based Vaccines for Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Synthetic Polypeptide Vaccines Table 18. Significant Companies of Recombinant Polypeptide Vaccine Table 19. Significant Companies of Other Table 20. Global Peptide-Based Vaccines for Cancer Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Peptide-Based Vaccines for Cancer Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Peptide-Based Vaccines for Cancer Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Peptide-Based Vaccines for Cancer Sales Volume Share by Type (2021-2026) Table 24. Global Peptide-Based Vaccines for Cancer Sales Volume Share by Type (2027-2032) Table 25. Global Peptide-Based Vaccines for Cancer Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Peptide-Based Vaccines for Cancer Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Peptide-Based Vaccines for Cancer Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Peptide-Based Vaccines for Cancer Sales Value Share by Type (2021-2026) Table 29. Global Peptide-Based Vaccines for Cancer Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Infectious Disease Prevention Table 31. Significant Companies of Cancer Immunotherapy Table 32. Significant Companies of Other Table 33. Global Peptide-Based Vaccines for Cancer Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Peptide-Based Vaccines for Cancer Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Peptide-Based Vaccines for Cancer Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Peptide-Based Vaccines for Cancer Sales Volume Share by Application (2021-2026) Table 37. Global Peptide-Based Vaccines for Cancer Sales Volume Share by Application (2027-2032) Table 38. Global Peptide-Based Vaccines for Cancer Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Peptide-Based Vaccines for Cancer Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Peptide-Based Vaccines for Cancer Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Peptide-Based Vaccines for Cancer Sales Value Share by Application (2021-2026) Table 42. Global Peptide-Based Vaccines for Cancer Sales Value Share by Application (2027-2032) Table 43. Global Peptide-Based Vaccines for Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Peptide-Based Vaccines for Cancer Sales by Region (2021-2026) & (K Units) Table 45. Global Peptide-Based Vaccines for Cancer Sales Market Share by Region (2021-2026) Table 46. Global Peptide-Based Vaccines for Cancer Sales by Region (2027-2032) & (K Units) Table 47. Global Peptide-Based Vaccines for Cancer Sales Market Share by Region (2027-2032) Table 48. Global Peptide-Based Vaccines for Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Peptide-Based Vaccines for Cancer Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Peptide-Based Vaccines for Cancer Sales Value Share by Region (2021-2026) Table 51. Global Peptide-Based Vaccines for Cancer Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Peptide-Based Vaccines for Cancer Sales Value Share by Region (2027-2032) Table 53. Global Peptide-Based Vaccines for Cancer Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Peptide-Based Vaccines for Cancer Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Peptide-Based Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Peptide-Based Vaccines for Cancer Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Peptide-Based Vaccines for Cancer Sales by Country (2021-2026) & (K Units) Table 58. Global Peptide-Based Vaccines for Cancer Sales Market Share by Country (2021-2026) Table 59. Global Peptide-Based Vaccines for Cancer Sales by Country (2027-2032) & (K Units) Table 60. Global Peptide-Based Vaccines for Cancer Sales Market Share by Country (2027-2032) Table 61. Global Peptide-Based Vaccines for Cancer Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Peptide-Based Vaccines for Cancer Sales Value Market Share by Country (2021-2026) Table 63. Global Peptide-Based Vaccines for Cancer Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Peptide-Based Vaccines for Cancer Sales Value Market Share by Country (2027-2032) Table 65. ACT Company Information Table 66. ACT Business Overview Table 67. ACT Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. ACT Peptide-Based Vaccines for Cancer Product Portfolio Table 69. ACT Recent Development Table 70. Almac Company Information Table 71. Almac Business Overview Table 72. Almac Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Almac Peptide-Based Vaccines for Cancer Product Portfolio Table 74. Almac Recent Development Table 75. AmbioPharm Company Information Table 76. AmbioPharm Business Overview Table 77. AmbioPharm Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio Table 79. AmbioPharm Recent Development Table 80. Anergis Company Information Table 81. Anergis Business Overview Table 82. Anergis Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Anergis Peptide-Based Vaccines for Cancer Product Portfolio Table 84. Anergis Recent Development Table 85. Immatics Company Information Table 86. Immatics Business Overview Table 87. Immatics Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Immatics Peptide-Based Vaccines for Cancer Product Portfolio Table 89. Immatics Recent Development Table 90. Immatics Company Information Table 91. Immatics Business Overview Table 92. Immatics Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Immatics Peptide-Based Vaccines for Cancer Product Portfolio Table 94. Immatics Recent Development Table 95. Marker Therapeutics, Inc. Company Information Table 96. Marker Therapeutics, Inc. Business Overview Table 97. Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio Table 99. Marker Therapeutics, Inc. Recent Development Table 100. OncoPep Company Information Table 101. OncoPep Business Overview Table 102. OncoPep Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. OncoPep Peptide-Based Vaccines for Cancer Product Portfolio Table 104. OncoPep Recent Development Table 105. Sellas Life Sciences Company Information Table 106. Sellas Life Sciences Business Overview Table 107. Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio Table 109. Sellas Life Sciences Recent Development Table 110. Ultimovacs Company Information Table 111. Ultimovacs Business Overview Table 112. Ultimovacs Peptide-Based Vaccines for Cancer Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio Table 114. Ultimovacs Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Peptide-Based Vaccines for Cancer Distributors List Table 118. Peptide-Based Vaccines for Cancer Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Peptide-Based Vaccines for Cancer Product Image Figure 2. Global Peptide-Based Vaccines for Cancer Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide-Based Vaccines for Cancer Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peptide-Based Vaccines for Cancer Sales (2021-2032) & (K Units) Figure 5. Global Peptide-Based Vaccines for Cancer Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Peptide-Based Vaccines for Cancer Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Synthetic Polypeptide Vaccines Image Figure 10. Recombinant Polypeptide Vaccine Image Figure 11. Other Image Figure 12. Global Peptide-Based Vaccines for Cancer Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Peptide-Based Vaccines for Cancer Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Peptide-Based Vaccines for Cancer Sales Volume Share by Type (2021-2032) Figure 15. Global Peptide-Based Vaccines for Cancer Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Peptide-Based Vaccines for Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Peptide-Based Vaccines for Cancer Sales Value Share by Type (2021-2032) Figure 18. Infectious Disease Prevention Image Figure 19. Cancer Immunotherapy Image Figure 20. Other Image Figure 21. Global Peptide-Based Vaccines for Cancer Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Peptide-Based Vaccines for Cancer Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Peptide-Based Vaccines for Cancer Sales Volume Share by Application (2021-2032) Figure 24. Global Peptide-Based Vaccines for Cancer Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Peptide-Based Vaccines for Cancer Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Peptide-Based Vaccines for Cancer Sales Value Share by Application (2021-2032) Figure 27. Global Peptide-Based Vaccines for Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Peptide-Based Vaccines for Cancer Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Peptide-Based Vaccines for Cancer Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Peptide-Based Vaccines for Cancer Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Peptide-Based Vaccines for Cancer Sales Value (2021-2032) & (US$ Million) Figure 32. North America Peptide-Based Vaccines for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Peptide-Based Vaccines for Cancer Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Peptide-Based Vaccines for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Peptide-Based Vaccines for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Peptide-Based Vaccines for Cancer Sales Value (2021-2032) & (US$ Million) Figure 38. South America Peptide-Based Vaccines for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Peptide-Based Vaccines for Cancer Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Peptide-Based Vaccines for Cancer Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Peptide-Based Vaccines for Cancer Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Peptide-Based Vaccines for Cancer Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Synthetic Polypeptide Vaccines
  • Recombinant Polypeptide Vaccine
  • Other
Applications
  • Infectious Disease Prevention
  • Cancer Immunotherapy
  • Other
Companies covered
  • ACT
  • Almac
  • AmbioPharm
  • Anergis
  • Immatics
  • Immatics
  • Marker Therapeutics, Inc.
  • OncoPep
  • Sellas Life Sciences
  • Ultimovacs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide-Based Vaccines for Cancer Sales Value (2021-2032)
  4. 1.2.2 Global Peptide-Based Vaccines for Cancer Sales Volume (2021-2032)
  5. 1.2.3 Global Peptide-Based Vaccines for Cancer Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peptide-Based Vaccines for Cancer Market Dynamics
  1. 2.1 Peptide-Based Vaccines for Cancer Industry Trends
  2. 2.2 Peptide-Based Vaccines for Cancer Industry Drivers
  3. 2.3 Peptide-Based Vaccines for Cancer Industry Opportunities and Challenges
  4. 2.4 Peptide-Based Vaccines for Cancer Industry Restraints
3 Peptide-Based Vaccines for Cancer Market by Company
  1. 3.1 Global Peptide-Based Vaccines for Cancer Company Revenue Ranking in 2025
  2. 3.2 Global Peptide-Based Vaccines for Cancer Revenue by Company (2021-2026)
  3. 3.3 Global Peptide-Based Vaccines for Cancer Sales Volume by Company (2021-2026)
  4. 3.4 Global Peptide-Based Vaccines for Cancer Average Price by Company (2021-2026)
  5. 3.5 Global Peptide-Based Vaccines for Cancer Company Ranking (2024-2026)
  6. 3.6 Global Peptide-Based Vaccines for Cancer Company Manufacturing Base and Headquarters
  7. 3.7 Global Peptide-Based Vaccines for Cancer Company Product Type and Application
  8. 3.8 Global Peptide-Based Vaccines for Cancer Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peptide-Based Vaccines for Cancer Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peptide-Based Vaccines for Cancer Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peptide-Based Vaccines for Cancer Market by Type
  1. 4.1 Peptide-Based Vaccines for Cancer Type Introduction
  2. 4.1.1 Synthetic Polypeptide Vaccines
  3. 4.1.2 Recombinant Polypeptide Vaccine
  4. 4.1.3 Other
  5. 4.2 Global Peptide-Based Vaccines for Cancer Sales Volume by Type
  6. 4.2.1 Global Peptide-Based Vaccines for Cancer Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide-Based Vaccines for Cancer Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Peptide-Based Vaccines for Cancer Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Peptide-Based Vaccines for Cancer Sales Value by Type
  10. 4.3.1 Global Peptide-Based Vaccines for Cancer Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Peptide-Based Vaccines for Cancer Sales Value by Type (2021-2032)
  12. 4.3.3 Global Peptide-Based Vaccines for Cancer Sales Value Share by Type (2021-2032)
5 Peptide-Based Vaccines for Cancer Market by Application
  1. 5.1 Peptide-Based Vaccines for Cancer Application Introduction
  2. 5.1.1 Infectious Disease Prevention
  3. 5.1.2 Cancer Immunotherapy
  4. 5.1.3 Other
  5. 5.2 Global Peptide-Based Vaccines for Cancer Sales Volume by Application
  6. 5.2.1 Global Peptide-Based Vaccines for Cancer Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide-Based Vaccines for Cancer Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Peptide-Based Vaccines for Cancer Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Peptide-Based Vaccines for Cancer Sales Value by Application
  10. 5.3.1 Global Peptide-Based Vaccines for Cancer Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peptide-Based Vaccines for Cancer Sales Value by Application (2021-2032)
  12. 5.3.3 Global Peptide-Based Vaccines for Cancer Sales Value Share by Application (2021-2032)
6 Peptide-Based Vaccines for Cancer Regional Sales and Value Analysis
  1. 6.1 Global Peptide-Based Vaccines for Cancer Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide-Based Vaccines for Cancer Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide-Based Vaccines for Cancer Sales by Region: 2021-2026
  4. 6.2.2 Global Peptide-Based Vaccines for Cancer Sales by Region (2027-2032)
  5. 6.3 Global Peptide-Based Vaccines for Cancer Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peptide-Based Vaccines for Cancer Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peptide-Based Vaccines for Cancer Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peptide-Based Vaccines for Cancer Sales Value by Region (2027-2032)
  9. 6.5 Global Peptide-Based Vaccines for Cancer Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peptide-Based Vaccines for Cancer Sales Value (2021-2032)
  12. 6.6.2 North America Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peptide-Based Vaccines for Cancer Sales Value (2021-2032)
  15. 6.7.2 Europe Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peptide-Based Vaccines for Cancer Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peptide-Based Vaccines for Cancer Sales Value (2021-2032)
  21. 6.9.2 South America Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peptide-Based Vaccines for Cancer Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peptide-Based Vaccines for Cancer Sales Value Share by Country, 2025 VS 2032
7 Peptide-Based Vaccines for Cancer Country-level Sales and Value Analysis
  1. 7.1 Global Peptide-Based Vaccines for Cancer Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide-Based Vaccines for Cancer Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peptide-Based Vaccines for Cancer Sales by Country (2021-2032)
  4. 7.3.1 Global Peptide-Based Vaccines for Cancer Sales by Country (2021-2026)
  5. 7.3.2 Global Peptide-Based Vaccines for Cancer Sales by Country (2027-2032)
  6. 7.4 Global Peptide-Based Vaccines for Cancer Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peptide-Based Vaccines for Cancer Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peptide-Based Vaccines for Cancer Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peptide-Based Vaccines for Cancer Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peptide-Based Vaccines for Cancer Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peptide-Based Vaccines for Cancer Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ACT
  2. 8.1.1 ACT Company Information
  3. 8.1.2 ACT Business Overview
  4. 8.1.3 ACT Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ACT Peptide-Based Vaccines for Cancer Product Portfolio
  6. 8.1.5 ACT Recent Developments
  7. 8.2 Almac
  8. 8.2.1 Almac Company Information
  9. 8.2.2 Almac Business Overview
  10. 8.2.3 Almac Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Almac Peptide-Based Vaccines for Cancer Product Portfolio
  12. 8.2.5 Almac Recent Developments
  13. 8.3 AmbioPharm
  14. 8.3.1 AmbioPharm Company Information
  15. 8.3.2 AmbioPharm Business Overview
  16. 8.3.3 AmbioPharm Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AmbioPharm Peptide-Based Vaccines for Cancer Product Portfolio
  18. 8.3.5 AmbioPharm Recent Developments
  19. 8.4 Anergis
  20. 8.4.1 Anergis Company Information
  21. 8.4.2 Anergis Business Overview
  22. 8.4.3 Anergis Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Anergis Peptide-Based Vaccines for Cancer Product Portfolio
  24. 8.4.5 Anergis Recent Developments
  25. 8.5 Immatics
  26. 8.5.1 Immatics Company Information
  27. 8.5.2 Immatics Business Overview
  28. 8.5.3 Immatics Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
  30. 8.5.5 Immatics Recent Developments
  31. 8.6 Immatics
  32. 8.6.1 Immatics Company Information
  33. 8.6.2 Immatics Business Overview
  34. 8.6.3 Immatics Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Immatics Peptide-Based Vaccines for Cancer Product Portfolio
  36. 8.6.5 Immatics Recent Developments
  37. 8.7 Marker Therapeutics, Inc.
  38. 8.7.1 Marker Therapeutics, Inc. Company Information
  39. 8.7.2 Marker Therapeutics, Inc. Business Overview
  40. 8.7.3 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Marker Therapeutics, Inc. Peptide-Based Vaccines for Cancer Product Portfolio
  42. 8.7.5 Marker Therapeutics, Inc. Recent Developments
  43. 8.8 OncoPep
  44. 8.8.1 OncoPep Company Information
  45. 8.8.2 OncoPep Business Overview
  46. 8.8.3 OncoPep Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 OncoPep Peptide-Based Vaccines for Cancer Product Portfolio
  48. 8.8.5 OncoPep Recent Developments
  49. 8.9 Sellas Life Sciences
  50. 8.9.1 Sellas Life Sciences Company Information
  51. 8.9.2 Sellas Life Sciences Business Overview
  52. 8.9.3 Sellas Life Sciences Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sellas Life Sciences Peptide-Based Vaccines for Cancer Product Portfolio
  54. 8.9.5 Sellas Life Sciences Recent Developments
  55. 8.10 Ultimovacs
  56. 8.10.1 Ultimovacs Company Information
  57. 8.10.2 Ultimovacs Business Overview
  58. 8.10.3 Ultimovacs Peptide-Based Vaccines for Cancer Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ultimovacs Peptide-Based Vaccines for Cancer Product Portfolio
  60. 8.10.5 Ultimovacs Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide-Based Vaccines for Cancer Value Chain Analysis
  2. 9.1.1 Peptide-Based Vaccines for Cancer Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide-Based Vaccines for Cancer Sales Mode & Process
  6. 9.2 Peptide-Based Vaccines for Cancer Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide-Based Vaccines for Cancer Distributors
  9. 9.2.3 Peptide-Based Vaccines for Cancer Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst